Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 1
  • Print publication year: 2005
  • Online publication date: February 2010

16 - Growth, nutrition, and metabolism

from Part II - General issues in the care of pediatric HIV patients

Summary

In recent years, growth, nutrition, and metabolism of HIV-infected children have been receiving increased attention for several reasons. It has been recognized for the past decade that HIV-infected children generally do not grow as well as their uninfected counterparts, but more recent evidence suggests that this is often true even in the face of adequate virologic control. Given also that growth is a predictor of survival, there has been closer scrutiny of nutritional and metabolic factors that can contribute to poor growth. Additionally, potentially serious metabolic complications of HIV infection and/or antiretroviral therapies overlap with nutritional aspects of the infection and have prompted attention to the pathophysiology of malnutrition in these children.

The current state of knowledge regarding the complex interrelationships of nutrition, HIV disease, antiretroviral therapy, and growth is reviewed in this chapter. Recommendations for nutritional monitoring and support are discussed, as are therapies for certain recognized causes of malnutrition in HIV-infected children. Briefly described are the complications and recommended treatments for fat redistribution, hyperlipidemia, insulin resistance, osteonecrosis, and mitochondrial toxicity. Finally, nutritional issues most germane to resource-poor settings are highlighted, as are areas in which further research is needed.

Definitions: malnutrition and growth failure

Pediatric HIV disease can lead to multiple nutritional deficiencies. Deficiencies of adequate macronutrients (protein or calories) and/or micronutrients (vitamins, minerals) to maintain optimal health status is referred to as undernutrition or, more commonly, malnutrition. Many definitions for growth failure or failure to thrive (FTT) exist.

REFERENCES
Baumgartner, R. N., Roche, A. F. & Himes, J. H.Incremental growth tables: supplementary to previously published charts. Am. J. Clin. Nutr. 43 (1986), 711–22
Miller, T. L.Nutrition in paediatric human immunodeficiency virus infection. Proc. Nutr. Soc. 59 (2000), 155–62
Beisel, W. R.Nutrition and immune function: overview. J. Nutr. 126 (1996), 2611–15S
Brown, K. H., Peerson, J. M., Rivera, J. & Allen, L. H.Effect of supplemental zinc on the growth and serum zinc concentrations of prepubertal children: a meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 75 (2002), 1062–71
Committee on Nutrition, American Academy of Pediatrics. Trace elements. In R. E. Kleinman (ed.), Pediatric Nutrition Handbook, 4th edn. Elk Grove, Ill: American Academy of Pediatrics. (1998), pp. 247–66
McKinney, R. E. & Robertson, W. R.Effect of human immunodeficiency virus infection on the growth of young children. J. Pediatr. 123 (1993), 579–82
Miller, T. L., Evans, S., Morris, V., Orav, E. J., McIntosh, K. & Winter, H. S.Growth and body composition in children with human immunodeficiency virus-1 infection. Am. J. Clin. Nutr. 57 (1993), 588–92
Moye, J. Jr., Rich, K. C., Kalish, L. A.. Natural history of somatic growth in infants born to women infected by human immunodeficiency virus. J. Pediatr. 128 (1996), 58–67
Saavedra, J. M., Henderson, R. A., Perman, J. A., Hutton, N., Livingston, R. A. & Yolken, R. H.Longitudinal assessment of growth in children born to mothers with human immunodeficiency virus infection. Arch. Pediatr. Adolesc. Med. 149 (1995), 497–502
Lindegren, M. L., Steinberg, S. & Byers, R. H.Epidemiology of Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome in children. Pediatr. Clin. N. Am. 47 (2000), 1–20
Kotler, D. P., Tierney, A. R., Wang, J. & Pierson, R. N.Magnitude of body cell mass depletion and the timing of death from wasting in Acquired Immune Deficiency Syndrome. Am. J. Clin. Nutr. 50 (1989), 444–7
Chlebowski, R. T., Grosvenor, M. B., Berhard, N. H., Morales, L. S. & Bulcavage, L. M.Nutritional status, gastrointestinal dysfunction, and survival in patients with Acquired Immune Deficiency Syndrome. Amer. J. Gastroenterol. 84 (1989), 1288–93
Lai, H., Lai, S., Shor-Posner, G., Ma, F., Trapido, E. & Baum, M. K.Plasma zinc, copper, copper:zinc ratio, and survival in a cohort of Human Immunodeficiency Virus-1-infected homosexual men. J. Acquir. Immune. Defic. Syndr. 27 (2001), 56–62
Tang, A. M., Graham, N. M. H., Semba, R. D. & Saah, A. J.Association between serum vitamin A and E levels and Human Immunodeficiency Virus-1 disease progression. Acquired Immune Deficiency Syndrome 11 (1997), 613–20
Baum, M. K., Shor-Posner, G, Lu, Y.. Micronutrients and Human Immunodeficiency Virus-1 disease progression. Acquired Immune Deficiency Syndrome 9 (1995), 1051–6
Cunningham-Rundles, S., Ahrn, S., Abuav-Nussbaum, R. & Dnistrian, A.Development of immunocompetence: role of micronutrients and microorganisms. Nutr. Rev. 60 (2002), S68–72
Chantry, C. J., Byrd, R. S., Englund, J. A.. Growth, survival and viral load in symptomatic childhood human immunodeficiency virus infection. Pediatr. Infect. Dis. J. 22(12) (2003), 1033–9
McKinney, R. E. Jr. & Wilfert, C.Growth as a prognostic indicator in children with human immunodeficiency virus infection treated with zidovudine. Acquired Immune Deficiency Syndrome Clinical Trials Group Protocol 043 Study Group. J. Pediatr. 125 (1994), 728–33
Berhane, R., Bagenda, D., Marum, L.. Growth failure as a prognostic indicator of mortality in pediatric Human Immunodeficiency Virus infection. Pediatrics 100 (1997), e7
Yong, F. H., Stanley, K., McKinney, R. E., et al. Prognostic value of plasma Ribonucleic Acid, CD4, and growth markers for clinical disease progression in children with Human Immunodeficiency Virus disease. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC) 38 (Sept 24–27, 1998), 364 [Abstract no. I-7]
Campa, A., Shor-Posner, G, Indacochea, F.. Mortality risk in selenium-deficient Human Immunodeficiency Virus-positive children. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol. 20 (1999), 508–13
Duggan, C. & Fawzi, W.Micronutrients and child health: studies in international nutrition and Human Immunodeficiency Virus infection. Nutr. Rev. 59 (2001), 358–69
Rodríguez, J. F., Cordero, J., Chantry, C. J.. Glutathione levels in Human Immunodeficiency Virus-infected children. Pediatr. Infect. Dis. J. 17 (1998), 236–41
Omene, J. A., Easington, C. R., Glew, R. H., Prosper, M. & Ledlie, S.Serum beta-carotene deficiency in Human Immunodeficiency Virus-infected children. J. Natl. Med. Assoc. 88 (1996), 789–93
Fawzi, W. W., Mbise, R. L., Hertzmark, E.. A randomized trial of vitamin A supplements in relation to mortality among human immunodeficiency virus-infected and uninfected children in Tanzania. Pediatr. Infect. Dis. J. 18 (1999), 127–33
Moye, J. Jr., Rich, K. C., Kalish, L. A.. Natural history of somatic growth in infants born to women infected by human immunodeficiency virus. Women and Infants Transmission Study Group. J. Pediatr. 128 (1996), 58–69
Miller, T. L., Evans, S., Orav, E. J., Morris, V., McIntosh, K. & Winter, H. S.Growth and body composition in children with human immunodeficiency virus-1 infection. Am. J. Clin. Nutr. 57 (1993), 588–92
Fontana, M., Zuin, G., Plebani, A.. Body composition in Human Immunodeficiency Virus-infected children: relations with disease progression and survival. Am. J. Clin. Nutr. 69 (1999), 1282–6
Arpadi, S. M., Cuff, P. A., Kotler, D. P.. Growth velocity, fat-free mass and energy intake are inversely related to viral load in Human Immunodeficiency Virus-infected children. J. Nutr. 130 (2000), 2498–502
Moye, J., Frederick, M., Chantry, C.. for the Women and Infants Transmission Study. 10-year follow-up of somatic growth in children born to women infected by human immunodeficiency virus. 8th Conf Retroviruses Opportunistic Infect. (Feb 4–8 2001) [Abstract 514]
Pollack, H., Glasberg, H., Lee, E.. Impaired early growth of infants perinatally infected with human immunodeficiency virus: Correlation with viral load. J. Pediatr. 130 (1997), 915–22
Miller, T. L., Easley, K. A., Zhang, W.. for the Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted Human Immunodeficiency Virus Infection (P2C2 Human Immunodeficiency Virus) Study Group, National Heart, Lung, and Blood Institute, Bethesda, MD. Maternal and infant factors associated with failure to thrive in children with vertically transmitted human immunodeficiency virus-1 infection: The prospective, P2C2 human immunodeficiency virus multicenter study. Pediatrics 108 (2001), 1287–96
Hilgartner, M. W., Donfield, S. M., Lynn, H. S.. The effect of plasma human immunodeficiency virus Ribonucleic Acid and Cluster of Differentiation4+ T lymphocytes on growth measurements of hemophilic boys and adolescents. Pediatrics 107 (2001), e56
Nachman, S. A., Lindsey, J. C., Pelton, S.. Growth in human immunodeficiency virus-infected children receiving ritonavir-containing antiretroviral therapy. Arch. Pediatr. Adolesc. Med. 156 (2002), 497–503
Buchacz, K., Cervia, J. S., Lindsey, J. C.. for the Pediatric Acquired Immune Deficiency Syndrome Clinical Trials Group 219 Study Team. Impact of protease inhibitor-containing combination antiretroviral therapies on height and weight growth in Human Immunodeficiency Virus-infected children. Pediatrics 108 (2001), e72
Verweel, G., Rossum, A. M. C., Hartwig, N. G., Wolfs, T. F., Scherpbier, H. J. & Groot, R.Treatment with highly active antiretroviral therapy in human immunodeficiency virus type-1-infected children is associated with a sustained effect on growth. Pediatrics 109 (2002), e25
Abrams, B., Duncan, D. & Hertz-Picciotto, H.A prospective study of dietary intake and acquired immune deficiency syndrome in Human Immunodeficiency Virus-seropositive homosexual men. J. Acquir. Immune. Defic. Syndr. 6 (1993), 949–58
Dunn, A. M., Cervia, J., Burgess, A.. Failure to thrive in the Human Immunodeficiency Virus-infected child. 11th Int Conf Acquired Immune Deficiency Syndrome 1 (1996), 319 [Abstract 2312]
Heller, L. S.Nutritional support for children with Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome. Acquired Immune Deficiency Syndrome Reader 10 (2000), 109–14
Allard, J. P., Aghdassi, E., Chau, J., Salit, I. & Walmsley, S.Oxidative stress and plasma antioxidant micronutrients in humans with Human Immunodeficiency Virus infection. Am. J. Clin. Nutr. 67 (1998), 1443–7
Mintz, M.Carnitine in human immunodeficiency virus type 1 infection/acquired immune deficiency syndrome. J. Child. Neurol. 10 (1995), 2S40–44
Haug, C. J., Aukrust, P., Haug, E., Morkrid, L., Muller, F. & Froland, S. S.Severe deficiency of 1,25-dihyroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J. Clin. Endocrinol. Metab. 83 (1998), 3832–8
Henderson, R. A., Talusan, K., Hutton, N., Yolken, R. H. & Caballero, B.Serum and plasma markers of nutritional status in children infected with the human immunodeficiency virus. J. Am. Diet. Assoc. 97 (1997), 1377–81
Skurnick, J. H., Bogden, J. D., Baker, H.. Micronutrient profiles in Human Immunodeficiency Virus-1-infected heterosexual adults. J. Acquired Immune Deficiency Syndrome 12 (1996), 75–83
Horlick, M., Arpadi, S. M., Bethel, J.. Bioelectrical impedance analysis models for prediction of total body water and fat-free mass in healthy and Human Immunodeficiency Virus-infected children and adolescents. Am. J. Clin. Nutr. 76 (2002), 991–9
Freedman, D. S., Serdula, M. K., Srnivasan, S. R. & Berenson, G. S.Relation of circumferences and skinfold thicknesses to lipid and insulin concentrations in children and adolescents: the Bogalusa Heart Study. Am. J. Clin. Nutr. 69 (1999), 308–17
Taylor, R. W., Jones, I. E., Williams, S. M. & Goulding, A.Evaluation of waist circumference, waist-to-hip ratio, and the conicity index as screening tools for high trunk fat mass, as measured by dual-energy X-ray absorptiometry, in children aged 3–19 years. Am. J. Clin. Nutr. 72 (2000), 490–5
Goran, M. I., Gower, B. A., Treuth, M. & Nagy, T. R.Prediction of intra-abdominal and subcutaneous abdominal adipose tissue in healthy pre-pubertal children. Int. Jr. Obes. Relat. Metab. Disord. 22 (1998), 549–68
Johann-Liang, R., Neill, L., Cervia, J.. Energy balance, viral burden, insulin-like growth factor-1, interleukin-6 and growth impairment in children infected with human immunodeficiency virus. Acquired Immune Deficiency Syndrome 14 (2000), 683–90
Guo, S., Roche, A. F., Foman, S. J.. Reference data on gains in weight and length during the first two years of life. J. Pediatr. 119 (1991), 355–62
Karlberg, P., Taranger, J., Engstrom, I.. I. Physical growth from birth to 16 years and longitudinal outcome of the study during the same age period. Acta. Pediatr. Scand. Suppl. 258 (1976), 7–76
Sentongo, T. A., Rutstein, R. M., Stettler, N.. Association between steatorrhea, growth, and immunologic status in children with perinatally acquired Human Immunodeficiency Virus infection. Arch. Pediatr. Adolesc. Med. 155 (2001), 149–53
Alfaro, M. P., Siegel, R. M., Baker, R. C. & Heubi, J. E.Resting energy expenditure and body composition in pediatric Human Immunodeficiency Virus infection. Pediatr. Acquired Immune Deficiency Syndrome Human Immunodeficiency Virus Infect. 6 (1995), 276–80
Henderson, R. A., Talusan, K., Hutton, N., Yolken, R. H. & Caballero, B.Resting energy expenditure and body composition in children with Human Immunodeficiency Virus infection. J. Acquired Immune Deficiency Syndrome Hum. Retrovirol. 19 (1998), 150–7
Clarick, R. H., Hanekom, W. A., Yogev, R. & Chadwick, E. G.Megestrol acetate treatment of growth failure in children infected with human immunodeficiency virus. Pediatrics, 99(3) (1997), 354–7
Mann, M., Koller, E., Murgo, A., Malozowski, S., Bacsanyi, J. & Leinung, M.Glucocorticoid like activity of megestrol: a summary of Food and Drug Administration experience and a review of the literature. Arch. Intern. Med. 15 (1997), 1651–6
Stockheim, J., Daaboul, J., Scully, S., Yogev, R.Scully, S. P., Binns, H. J. & Chadwick, E.Adrenal suppression in Human Immunodeficiency Virus-infected children treated with megestrol acetate. J. Pediatr. 134(3) (1999), 368–70
Chantry, C., González de Pijem, L., Febo, I. & Lugo, L.Adrenal suppression secondary to megestrol acetate in Human Immunodeficiency Virus-infected children. 12th Int. Conf. Acquired Immune Deficiency Syndrome (July 1998), 610 [Abstract 32445]
Brady, M. T., Korany, K. I. & Hunkler, J. A.Megestrol acetate for the treatment of anorexia associated with human immunodeficiency virus infection in children. Pediatr. Inf. Dis. J. 13 (1994), 754–6
Briefel, R. R. & Woteki, C. E.Development of Food Sufficiency Questions for the Third National Health and Nutrition Examination Survey. J. Nutr. Educ. 24 (1992), 24S–8S
Henderson, R. A., Saavedra, J. M., Perman, J. A., Hutton, N., Livingston, R. A. & Yolken, R. H.Effect of enteral tube feeding on growth of children with symptomatic human immunodeficiency virus infection. J. Pediatr. Gastroenterol. Nutr. 18 (1994), 429–34
Miller, T. L., Awnetwant, E. L., Evans, S., Morris, V. M., Vazquez, I. M. & McIntosh, K.Gastrostomy tube supplementation for Human Immunodeficiency Virus infected children. Pediatrics 96 (1995), 696–702
Sinden, A. A., Dillard, V. L. & Sutphen, J. L. Enteral nutrition. In W. A., Walker, P. R., Durie, J. R., Hamilton, J. A., Walker-Smith & J. B. Watkins (eds.), Pediatric Gastrointestinal Disease. Philadelphia, PA: BC Decker, Inc. (1991), p. 1636
Miller, T. L., Orav, E. J., Martin, S. R.. Malnutrition and carbohydrate malabsorption in children with vertically-transmitted human immunodeficiency virus-1 infection. Gastroenterology 100 (1991), 1296–302
The Italian Pediatric Intestinal/Human Immunodeficiency Virus Study Group. Intestinal malabsorption of Human Immunodeficiency Virus-infected children: relationship to diarrhea, failure to thrive, enteric micro-organisms and immune impairment. Acquired Immune Deficiency Syndrome 7 (1993), 1435–40
Mulligan, K., Tai, V. W. & Schambelan, M.Energy expenditure in human immunodeficiency virus infection [letter]. New Engl. J. Med. 70 (1997), 70–1
Chiarelli, F., Galli, L., Verrotti, A., diRocco, L., Vierucci, A. & Martino, M.Thyroid function in children with perinatal human immunodeficiency virus type 1 infection. Thyroid 10 (2000), 499–505
Laue, L., Pizzo, P. A., Butler, K. & Cutler, G. B. Jr. Growth and neuroendocrine dysfunction in children with acquired immunodeficiency syndrome. J. Pediatr. 117 (1990), 541–5
Jospe, N. &Powell, K. R.Growth hormone deficiency in an 8-year old girl with human immunodeficiency virus infection. Pediatrics 86 (1990), 309–12
Cieslak, T. J., Ascher, D. P., Zimmerman, P. A.. Adrenal insufficiency presenting as Human Immunodeficiency Virus wasting syndrome in a child: initial successful response to megestrol. Pediatr. Acquired Immune Deficiency Syndrome Human Immunodeficiency Virus Infect. 2 (1991), 279–83
Frost, R. A., Nachman, S. A., Lang, C. H. & Gelato, M. C.Proteolysis of insulin-like growth factor-binding protein-3 in human immunodeficiency virus-positive children with failure to thrive. J. Clin. Endocrinol. Metab. 81 (1996), 2957–62
Guyda, H. J.How do we best measure growth hormone action?Horm. Res. 48 (Suppl. 5) (1997), 1–10
Gelato, M. C. & Frost, R. A.IGFBP-3. Functional and structural implications in aging and wasting syndromes. Endocrine 7: 1 (1997), 81–5
Mahoney, E. M., Donfield, S. M., Howard, C., Kaufman, F. & Gerner, J. M.Human Immunodeficiency Virus-associated immune dysfunction and delayed pubertal development in a cohort of young hemophiliacs. Hemophilia Growth and Development Study. J. Acquired Immune Deficiency Syndrome 21 (1999), 333–7
Arnalich, F., Martinez, P., Hernanz, A.. Altered concentrations of appetite regulators may contribute to the development and maintenance of Human Immunodeficiency Virus-associated wasting. Acquired Immune Deficiency Syndrome 11 (1997), 1129–34
Martino, M., Galli, L., Chiarelli, F.. Interleukin-6 release by cultured peripheral blood mononuclear cells inversely correlates with height velocity, bone age, insulin-like growth factor-I, and insulin-like growth factor binding protein-3 serum levels in children with perinatal Human Immunodeficiency Virus-1 infection. Clin. Immunol. 94 (2000), 212–18
Mynarcik, D. C., Frost, R. A., Lang, C. H.. Insulin-like growth factor system in patients with Human Immunodeficiency Virus infection: effect of exogenous growth hormone administration. J. Acquired Immune Deficiency Syndrome 22 (1999), 49–55
Chantry, C., Cervia, J., Hughes, M., Patra, K., Hodge, J., Moye, J. and the Pediatric Acquired Immune Deficiency Syndrome Clinical Trials Group Protocol 1010 Team. Body composition and biochemical changes in children starting or switching combination antiretroviral therapy. 10th Conf. Retroviruses Opportunistic Infect. 2003 [Abstract No. 775]
Pinto, G., Blanche, S., Thiriet, I., Souberbielle, J. C., Goulet, O. & Brauner, R.Growth hormone treatment of children with human immunodeficiency virus-associated growth failure. Eur. J. Pediatr. 159 (2000), 937–8
Fox-Wheeler, S., Heller, L., Salata, C. M.. Evaluation of the effects of oxandrolone on malnourished Human Immunodeficiency Virus-positive pediatric patients. Pediatrics 104 (1999), e73
Lo, J. C., Mulligan, K., Noor, M. A.. The effects of recombinant human growth hormone on body composition and glucose metabolism in Human Immunodeficiency Virus-infected patients with fat accumulation. J. Clin. Endocrinol. Metab. 8 (2001), 3480–7
Dreimane, D., Gallagher, K., Nielsen, K.. Growth hormone exerts potent anabolic effects in an adolescent with human immunodeficiency virus wasting. Pediatr. Infect. Dis. J. 18 (1999), 167–9
Grinspoon, S., Corcoran, C., Stanley, T., Katznelson, L. & Klibanski, A.Effects of androgen administration on the growth hormone-insulin-like growth factor I axis in men with acquired immunodeficiency syndrome wasting. J. Clin. Endocrinol. Metab. 83 (1998), 4251–6
Brambilla, P., Bricalli, D., Sala, N.. Highly active antiretroviral-treated Human Immunodeficiency Virus-infected children show fat distribution changes even in absence of lipodystrophy. Acquired Immune Deficiency Syndrome 15 (2001), 2415–22
Arpadi, S. M., Cuff, P. A., Horlick, M., Wang, J. & Kotler, D. R.Lipodystrophy in Human Immunodeficiency Virus-infected children is associated with high viral load and low Cluster of Differentiation4+-lymphocyte count and Cluster of Differentiation4+-lymphocyte percentage at baseline and use of protease inhibitors and stavudine. J. Acquired Immune Deficiency Syndrome 27 (2001), 30–4
Melvin, A. J., Lennon, S., Mohan, K. M. & Purnell, J. Q.Metabolic abnormalities in Human Immunodeficiency Virus type 1-infected children treated and not treated with protease inhibitors. Acquired Immune Deficiency Syndrome Res. Hum. Retroviruses 17 (2001), 1117–23
Amaya, R. A., Kozinetz, C. A., McMeans, A., Schwarzwald, H., & Kline, M. W.Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 21 (2002), 405–10
Jaquet, D., Levine, M., Ortega-Rodriguez, E.. Clinical and metabolic presentation of the lipodystrophic syndrome in Human Immunodeficiency Virus-infected children. Acquired Immune Deficiency Syndrome 14 (2000), 2123–8
Wanke, C., Gerrior, J., Kantaros, J., Coakley, E. & Albrecht, M.Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with Human Immunodeficiency Virus. Acquired Immune Deficiency Syndrome 13 (1999), 2099–103
Hadigan, C., Corcoran, C., Basgoz, N., Davis, B., Sax, P. & Grinspoon, S.Metformin in the treatment of Human Immunodeficiency Virus lipodystrophy syndrome: a randomized controlled trial. J. Am. Med. Assoc. 284 (2000), 472–7
Carr, A., Hudson, J., Chuah, J.. Human Immunodeficiency Virus protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. Acquired Immune Deficiency Syndrome 15 (2001), 1811–22
Hatano, H., Miller, K. D., Yoder, C. P.. Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy. Acquired Immune Deficiency Syndrome 14 (2000), 1935–42
Dube, M. P., Sprecher, D., Henry, W. K.. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendations of the Adult Acquired Immune Deficiency Syndrome Clinical Trial Group Cardiovascular Disease Focus Group. Clin. Infect. Dis. 31 (2000), 1216–24
Moyle, G. J., Lloyd, M., Reynolds, B., Baldwin, C., Mandalia, S. & Gazzord, B. G.Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. Acquired Immune Deficiency Syndrome 15 (2001), 1503–8
Jones, S. P., Doran, D. A., Leatt, P. B., Maher, B. & Pirmohamed, M.Short-term exercise training improves body composition and hyperlipidaemia in Human Immunodeficiency Virus-positive individuals with lipodystrophy. [letter] Acquired Immune Deficiency Syndrome 15 (2001), 2049–51
Arpadi, S. M., Horlick, M., Thornton, J., Cuff, P. A., Wang, J. & Kotler, D. P.Bone mineral content is lower in prepubertal Human Immunodeficiency Virus-infected children. J. Acquired Immune Deficiency Syndrome 29 (2002), 450–4
Mora, S., Sala, N., Bricalli, D.. Bone mineral loss through increased bone turnover in Human Immunodeficiency Virus-infected children treated with highly active antiretroviral therapy. Acquired Immune Deficiency Syndrome 15 (2001), 1823–9
Tebas, P., Powderly, W. G., Claxton, S.. Accelerated bone mineral loss in Human Immunodeficiency Virus-infected patients receiving potent antiretroviral therapy. Acquired Immune Deficiency Syndrome 14 (2000), F63–7
O'Brien, K. O., Razavi, M., Henderson, R. A., Caballero, B. & Ellis, K. J.Bone mineral content in girls perinatally infected with Human Immunodeficiency Virus. Am. J. Clin. Nutr. 73 (2001), 821–6
Aukrust, P., Haug, C. J., Ueland, T.. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J. Clin. Endocrinol. Metab. 84 (1999), 145–50
Tan, B. M., Nelson, R. P., James-Yarish, M, Emmanuel, P. J. & Schurman, S. J.Bone metabolism in children with human immunodeficiency virus infection receiving highly active anti-retroviral therapy including a protease inhibitor. J. Pediatr. 139 (2001), 447–51
Brown, P. &Crane, L.Avascular necrosis of bone in patients with human immunodeficiency virus infection: report of 6 cases and review of the literature. Clin. Infect. Dis. 32 (2001), 1221–6
Gaughan, D. M., Mofenson, L. M. & Hughes, M. D.Ostenecrosis of the hip (Legg—Calve—Perthes Disease) in human immunodeficiency virus-infected children. Pediatrics 109 (2002), e74
Sugerman, R. W., Church, J. A., Goldsmith, J. C. & Ens, G. E.Acquired protein S deficiency in children infected with human immunodeficiency virus. Pediatr. Infect. Dis. J. 15 (1996), 106–11
Eldridge, J., Dilley, A., Austin, H., et al. The role of protein C, protein S, and resistance to activated protein C in Legg-Perthes disease. Pediatrics 107 (2001), 1329–34
Cote, H. C., Brumme, Z. L., Craib, K. J.. Changes in mitochondrial Deoxyribonucleic Acid as a marker of nucleoside toxicity in Human Immunodeficiency Virus-infected patients. New Engl. J. Med. 346 (2002), 811–20
Glesby, M. J.Overview of mitochondrial toxicity of nucleoside reverse transcriptase inhibitors. Topics in Human Immunodeficiency Virus Med. 10 (2002), 42–6
The Perinatal Safety Review Working Group. Nucleoside exposure in the children of Human Immunodeficiency Virus-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. J. Acquired Immune Deficiency Syndrome 25 (2000), 261–8
Moyle, G.Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin. Ther. 22 (2000), 911–36
Falco, V., Rodriguez, D., Ribera, E.. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin. Infect. Dis. 34 (2002), 838–46
McComsey, G. A. & Lederman, M. M.High doses of riboflavin and thiamine may help in secondary prevention of hyperlactatemia. Acquired Immune Deficiency Syndrome Reader 12 (2002), 222–4
Arrigoni-Martelli, E. & Caso, V.Carnitine protects mitochondria and removes toxic acyls from xenobiotics. Drugs Exp. Clin. Res. 27 (2001), 27–49
Fawzi, W. W., Mbise, R. L., Hertzmark, E.. A randomized trial of vitamin A supplements in relation to mortality among human immunodeficiency virus-infected and uninfected children in Tanzania. Pediatr. Infect. Dis. J. 18 (1999), 127–33
Filteau, S. M., Rollins, N. C., Coutsoudis, A., Sullivan, K. R., Willumsen, J. F. & Tomkins, A. N.The effect of antenatal vitamin A and beta-carotene supplementation on gut integrity of infants of Human Immunodeficiency Virus-infected South African women. J. Pediatr. Gastroenterol. Nutr. 32 (2001), 464–70
Fawzi, W. W., Msamanga, G. I., Spiegelman, D.. Randomised trial of effects of vitamin supplements on pregnancy outcomes and T cell counts in Human Immunodeficiency Virus-1 infected women in Tanzania. Lancet 351 (1998), 1477–82
Amadi, B., Kelly, P., Mwiya, M.. Intestinal and systemic infection, Human Immunodeficiency Virus, and mortality in Zambian children with persistent diarrhea and malnutrition. J. Pediatr. Gastroenterol. Nutr. 32 (2001), 550–4